摘要
目的:分析参附注射液对缓慢性心律失常患者双腔心脏起搏器植入术后预后的影响。方法:选取2016年2月~2018年8月我院收治的缓慢性心律失常患者80例为研究对象,随机分为观察组、对照组各40例,对照组在行双腔心脏起搏器植入术同时予以常规治疗,观察组另予以参附注射液治疗7d,记录两组入院时、治疗3d、治疗7d心率(HR)及治疗前后心脏功能[血清脑钠肽(NT-proBNP)、心肌肌钙蛋白(cTnT)、左室射血分数(LVEF)、心脏功能评分(Marshall)]、神经功能[神经功能缺损评分(NFI)、血清神经元特异性烯醇化酶(NSE)、S-100β蛋白(S-100β)]、预后情况[格拉斯哥预后评分(GOS)及不良反应。结果:观察组治疗3d、治疗7d HR均明显高于对照组;治疗后14d,观察组血清NT-proBNP、cTnT及Marshall评分低于对照组,而LVEF较对照组高;治疗后14d观察组NFI评分低于对照,而血清NSE、S-100β水平高于对照组;观察组治疗后3个月GOS分级优于对照组;两组不良反应发生率比较差异无统计学意义。结论:参附注射液用于缓慢性心律失常可明显改善患者双腔心脏起搏器植入术后预后,促进其心功能及神经功能恢复,安全可靠,有推广价值。
Objective To analyze the effect of Shenfu injection on the prognosis of patients with bradyarrhythmia after dual-chamber pacemaker implantation.Methods 80 patients with bradyarrhythmia in our hospital from February 2016 to August 2018 were selected,they were randomly divided into observation group and control group,40 cases in each group.The control group was treated with dual-chamber pacemaker implantation and routine treatment,the observation group was treated with Shenfu injection for 7 days on the basis of the control group.The heart rate(HR)at admission,on 3d,7d after treatment,cardiac function before and after treatmen[t serum brain natriuretic peptide(NT-proBNP),cardiac troponin(cTnT),left ventricular ejection fraction(LVEF),cardiac function score(Marshall)],neurological function[neural function defect score(NFI),serum neuron specific enolase(NSE),S-100βprotein(S-100β)],prognosis[Glasgow Prognostic Score(GOS)and adverse reactions]in the two groups were recorded.Results The HR in the observation group was significantly higher than that in the control group on 3d,7d after treatment.On 14 days after treatment,the serum NT-proBNP,cTnT and Marshall scores in the observation group were lower than those in the control group,while the LVEF was higher than that of the control group.The NFI score of the observation group was lower than that of the control on 14d after treatment,the serum NSE and S-100βlevels were higher than those of the control group.The GOS grade of the observation group was better than that of the control group 3 months after treatment.There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Shenfu injection for bradyarrhythmia can significantly improve the prognosis of patients with dual-chamber pacemaker implantation,promote the recovery of cardiac function and nerve function,it is safe and reliable and has a promotion value.
作者
周小燕
张露丹
黄岑
Zhou Xiao-yan;Zhang Lu-dan;Huang Cen(Department of Cardiology,West China Hospital,Sichuan University,Chengdu 610041,China)
出处
《湖南师范大学学报（医学版）》
2019年第6期57-60,共4页
Journal of Hunan Normal University(Medical Sciences)
关键词
参附注射液
缓慢性心律失常
双腔心脏起搏器植入术
预后
影响
shenfu injection
bradyarrhythmia
dual-chamber cardiac pacemaker implantation
prognosis
influence
